Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Sep 15, 2025 · Filed Sep 17, 2025
Bicara Therapeutics's Chief Legal Officer sold $182K of Bicara Therapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$181,875
Shares × reported transaction price
34 days after results of Aug 12, 2025, 56 days before results of Nov 10, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
Fund moves
3 tracked managers disclosed the same change for Q2 2025. From a 13F filed Aug 14, 2025 covering holdings at Jun 30, 2025 — a quarter-end snapshot, not a live trade.
Fund moves
3 tracked managers disclosed the same change for Q2 2025. From a 13F filed Aug 13, 2025 covering holdings at Jun 30, 2025 — a quarter-end snapshot, not a live trade.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.